Physician profile
Mark Glodener
NPI 1174629885
$15,747.96
in general payments reported to CMS, 2019-2025
65 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,429 · 2020: $2,157 · 2021: $3,692 · 2022: $1,641 · 2023: $1,720 · 2024: $2,298 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,828.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,817.32 | 2019-2025 | |
| Lilly USA, LLC | $1,376.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,360.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,227.06 | 2021 | |
| Sanofi-Aventis U.S. LLC | $959.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $841.89 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $839.44 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $774.66 | 2019-2025 | Trintellix, Takhzyro |
| Glaxosmithkline, LLC. | $604.10 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $448.32 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $431.45 | 2019-2022 | |
| Allergan, INC. | $414.22 | 2019-2020 | |
| Corium, LLC | $344.93 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $278.30 | 2021-2023 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $256.91 | 2019-2024 | Livalo, Seglentis |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $227.46 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Csl Behring | $203.46 | 2019-2025 | Haegarda, Andembry |
| Upsher-Smith Laboratories LLC | $193.12 | 2020-2021 | |
| Inari Medical, INC. | $189.06 | 2022 | |
| Amarin Pharma, INC. | $183.73 | 2019-2022 | |
| Exact Sciences Corporation | $171.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $166.95 | 2019-2023 | |
| Abbott Laboratories | $157.46 | 2020-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $156.30 | 2022-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $155.46 | 2024 | Nexletol, Nexlizet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.45 | 2020-2024 | Ofev, Jardiance |
| Mannkind Corporation | $123.61 | 2019-2022 | |
| Corcept Therapeutics | $108.37 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $105.89 | 2023 | Auvelity |
| Cranial Technologies, INC | $103.94 | 2021-2025 | Doc Band |
| Sanofi Pasteur INC. | $95.55 | 2019-2023 | |
| Ultragenyx Pharmaceutical INC. | $90.41 | 2022-2023 | |
| Teleflex LLC | $86.59 | 2025 | Barrigel |
| Gilead Sciences, INC. | $83.71 | 2019-2020 | |
| Noven Therapeutics, LLC | $79.70 | 2023-2024 | Xelstrym |
| Eisai INC. | $64.31 | 2019-2020 | |
| Tris Pharma INC | $58.05 | 2023-2024 | Dyanavel Xr |
| Genentech USA, INC. | $51.73 | 2019-2021 | |
| Neos Therapeutics, Lp | $48.28 | 2020-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Arbor Pharmaceuticals, INC. | $48.18 | 2020-2021 | |
| Ibsa Pharma INC. | $47.57 | 2020-2023 | Tirosint, Licart |
| Biofire Diagnostics, LLC | $46.71 | 2020 | |
| Biocryst US Sales Co., LLC | $45.48 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.34 | 2022 | |
| Ironshore Pharmaceuticals INC. | $40.73 | 2019-2021 | |
| Pharming Healthcare, INC. | $39.65 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.60 | 2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $37.42 | 2023 | Quviviq |
| Seqirus USA INC | $33.74 | 2022-2024 | Fluad, Flucelvax |
| Currax Pharmaceuticals LLC | $29.43 | 2020-2023 | Contrave |
| Circassia INC. | $28.35 | 2019 | |
| Shire North American Group INC | $24.96 | 2019 | |
| Horizon Therapeutics Plc | $22.75 | 2020 | |
| Alk-Abello, INC | $22.39 | 2025 | Neffy |
| Tolmar, INC. | $22.08 | 2025 | Jatenzo |
| Inspire Medical Systems, INC. | $21.62 | 2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $20.22 | 2024 | Nuzyra |
| Bausch Health US, LLC | $19.35 | 2022 | |
| Phadia US INC. | $15.96 | 2023 | Immunocap |
| Bayer Healthcare Pharmaceuticals INC. | $15.54 | 2025 | |
| Philips North America LLC | $14.98 | 2024 | (Ck7) Extended Holter |
| Linus Health, INC. | $14.09 | 2024 | Core Cognitive Evaluation |
| Redhill Biopharma INC. | $12.65 | 2022 | |
| Kaleo, INC. | $11.36 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,031,504.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Glodener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.